Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by HarveyTwofaceon Nov 28, 2020 3:39pm
220 Views
Post# 31995213

RE:The news releases sure look like they could be plentiful ...

RE:The news releases sure look like they could be plentiful ...Mr. Mugs, I'd like to hear your personal interpretation of what the $30B opportunity means? Since general consensus among market researchers seem to be that the entire NSAID market is valued at around $16B 2019/2020 (just Google NSAID market value) then how can OTENA have an opportunity worth almost double the money? I know these are not your numbers, you are reporting what Antibe/Dan mentioned, but how do you personally think they want us all to understand/interpret this number ($30B), where does it come from, how did they come up with a number greater than the entire market for NSAID's ? What does the $30B opportunity consist of? Is it the (conservative) expected total sales of OTENA for osteothritis during the entire time for validity of their patent? Do you think they have included other indications in this (possibly) expected sales figure? Or are they thinking that ATE-352 will grab huge part of the opioid market share and included the numbers into this $30B opportunity? I am just asking to hear your thoughts, not to baisse your words or Dans, I value your input here on the board so am just curious. I know you don't know how Dan thinks or how he came up with that $30B...but you probably must have tried to understand the numbers too Just want to hear your opinion on this. With respect,
<< Previous
Bullboard Posts
Next >>